Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.34 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.34 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12729976 | 0.89 | CYP3A4 (0.46) | ALDH1A1MEN1KMT2ATSHRCYP3A4 | |
| SCHEMBL3809356 | 0.86 | CYP3A4 (0.46) | ALDH1A1SMN1; SMN2MEN1KMT2ATSHR | |
| SCHEMBL18856352 | 0.84 | CYP3A4 (0.49) | ALDH1A1SMN1; SMN2MEN1KMT2ATSHR | |
| SCHEMBL15133558 | 0.83 | TSHR (0.35) | ALDH1A1MEN1KMT2ATSHRCYP3A4 | |
| SCHEMBL13471757 | 0.82 | SMN1; SMN2 (0.41) | ALDH1A1SMN1; SMN2MEN1KMT2ATSHR | |
| SCHEMBL3904364 | 0.81 | TSHR (0.44) | ALDH1A1SMN1; SMN2MEN1KMT2ATSHR | |
| SCHEMBL12786987 | 0.81 | TSHR (0.35) | ALDH1A1MEN1KMT2ATSHRCYP3A4 | |
| SCHEMBL7219456 | 0.79 | CYP3A4 (0.62) | ALDH1A1TSHRCYP3A4TDP1ATM | |
| SCHEMBL12964713 | 0.79 | ALDH1A1 (0.39) | ALDH1A1SMN1; SMN2MEN1KMT2ATSHR | |
| SCHEMBL16433854 | 0.79 | PRKCA (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170258751-A1 | METHODS OF TREATING HEART FAILURE USING FATTY ACID FUMARATE DERIVATIVES | RAJASEKHAR VIJAYKUMAR (US) | 2017-09-14 | — | — | US | disclosed |
| US-20170144972-A1 | METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | CATABASIS PHARMACEUTICALS, INC. | 2017-05-25 | — | — | US | disclosed |
| US-20160340294-A1 | FATTY ACID FUMARATE DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2016-11-24 | — | — | US | disclosed |
| US-20160129122-A1 | FATTY ACID ANTIVIRAL CONJUGATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2016-05-12 | — | — | US | disclosed |
| US-20160106712-A1 | FATTY ACID COX INHIBITOR DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS INC (US) | 2016-04-21 | — | — | US | disclosed |
| US-9289503-B2 | Fatty acid fumarate derivatives and their uses | CATABASIS PHARMACEUTICALS, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-9216224-B2 | Fatty acid COX inhibitor derivatives and their uses | CATABASIS PHARMACEUTICALS, INC. (US) | 2015-12-22 | — | — | US | disclosed |
| US-20150352094-A1 | USE OF FATTY ACID NIACIN CONJUGATES FOR TREATING DISEASES | CATABASIS PHARMACEUTICALS, INC. | 2015-12-10 | — | — | US | disclosed |
| US-20150344430-A1 | METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | CATABASIS PHARMACEUTICALS, INC. | 2015-12-03 | — | — | US | disclosed |
| US-9150504-B2 | Fatty acid guanidine and salicylate guanidine derivatives and their uses | CATABASIS PHARMACEUTICALS, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-20150238618-A1 | FATTY ACID FUMARATE DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2015-08-27 | — | — | US | disclosed |
| US-9084826-B2 | Fatty acid conjugates of statin and FXR agonists; compositions and method of uses | CATABASIS PHARMACEUTICALS, INC. (US) | 2015-07-21 | — | — | US | disclosed |
| US-8969354-B2 | Fatty acid fumarate derivatives and their uses | CATABASIS PHARMACEUTICALS, INC. (US) | 2015-03-03 | — | — | US | disclosed |
| US-8946451-B2 | Lipoic acid acylated salicylate derivatives and their uses | CATABASIS PHARMACEUTICALS, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-20130244966-A1 | FATTY ACID ANTIVIRAL CONJUGATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130190327-A1 | BIS-FATTY ACID CONJUGATES AND THEIR USES | CATABASIS PHARMACEUTICALS INC (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130045939-A1 | FATTY ACID MACROLIDE DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2013-02-21 | — | — | US | disclosed |
| US-20120283292-A1 | FATTY ACID LENALIDOMIDE AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2012-11-08 | — | — | US | disclosed |
| US-20110082210-A1 | FATTY ACID FIBRATE DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2011-04-07 | — | — | US | disclosed |
| US-20110082192-A1 | LIPOIC ACID ACYLATED SALICYLATE DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2011-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130244966-A1 | FATTY ACID ANTIVIRAL CONJUGATES AND THEIR USES | FABP1, FABP2, HAVCR2 | ALDH1A1 1235/4885SMN1; SMN2 2004/4885MEN1 4824/4885 |
| US-20170258751-A1 | METHODS OF TREATING HEART FAILURE USING FATTY ACID FUMARATE DERIVATIVES | FH, FABP3, HMGCR | ALDH1A1 1637/4885SMN1; SMN2 2177/4885MEN1 4528/4885 |
| US-20150238618-A1 | FATTY ACID FUMARATE DERIVATIVES AND THEIR USES | FH, FASN, ELOVL1 | ALDH1A1 972/4885SMN1; SMN2 377/4885MEN1 3777/4885 |
| US-20150344430-A1 | METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | PCSK9, PCSK6, PCSK7 | ALDH1A1 3440/4885SMN1; SMN2 4499/4885MEN1 1682/4885 |
| US-20160106712-A1 | FATTY ACID COX INHIBITOR DERIVATIVES AND THEIR USES | PTGES, PTGES2, ALOX5 | ALDH1A1 676/4885SMN1; SMN2 1109/4885MEN1 4477/4885 |
| US-20130190327-A1 | BIS-FATTY ACID CONJUGATES AND THEIR USES | FASN, ELOVL1, ELOVL5 | ALDH1A1 610/4885SMN1; SMN2 222/4885MEN1 2326/4885 |
| US-20150352094-A1 | USE OF FATTY ACID NIACIN CONJUGATES FOR TREATING DISEASES | NAMPT, NNT, FASN | ALDH1A1 626/4885SMN1; SMN2 1126/4885MEN1 1675/4885 |
| US-20170144972-A1 | METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | PCSK9, PCSK6, PCSK7 | ALDH1A1 3440/4885SMN1; SMN2 4499/4885MEN1 1682/4885 |
| US-20160129122-A1 | FATTY ACID ANTIVIRAL CONJUGATES AND THEIR USES | FABP1, FABP2, HAVCR2 | ALDH1A1 1235/4885SMN1; SMN2 2004/4885MEN1 4824/4885 |
| US-20160340294-A1 | FATTY ACID FUMARATE DERIVATIVES AND THEIR USES | FH, FASN, ELOVL1 | ALDH1A1 972/4885SMN1; SMN2 377/4885MEN1 3777/4885 |
| US-20120283292-A1 | FATTY ACID LENALIDOMIDE AND THEIR USES | ELOVL1, FASN, FFAR2 | ALDH1A1 794/4885SMN1; SMN2 1929/4885MEN1 1768/4885 |
| US-20110082210-A1 | FATTY ACID FIBRATE DERIVATIVES AND THEIR USES | FABP1, PPARA, FABP4 | ALDH1A1 857/4885SMN1; SMN2 2753/4885MEN1 4622/4885 |
| US-20110082192-A1 | LIPOIC ACID ACYLATED SALICYLATE DERIVATIVES AND THEIR USES | ACACA, ACAT2, ACACB | ALDH1A1 188/4885SMN1; SMN2 2808/4885MEN1 3156/4885 |
| US-20130045939-A1 | FATTY ACID MACROLIDE DERIVATIVES AND THEIR USES | FASN, ELOVL3, FFAR2 | ALDH1A1 3822/4885SMN1; SMN2 3863/4885MEN1 4330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.